Indication
Neuroendocrine tumor of pancreas
3 clinical trials
3 products
Product
[212Pb]VMT-α-NETClinical trial
A Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1, First-in-human Clinical Trial of [212Pb] VMT-alpha-NET Using a Forward Dosimetric Planning Technique to Treat Refractory or Relapsed Neuroendocrine TumorsStatus: Active (not recruiting), Estimated PCD: 2026-11-20
Product
VMT-α-NETClinical trial
Randomized Phase II Trial of Everolimus 5 mg vs 10 mg/Daily for Patients With Advanced Neuroendocrine TumorsStatus: Recruiting, Estimated PCD: 2026-05-20
Product
Everolimus